OnKure Therapeutics, Inc. (OKUR)
Market: NASD |
Currency: USD
Address: 6707 Winchester Circle
OnKure Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of precision medicines that target biologically validated drivers of cancers. Its lead product candidate includes OKI-219, a selective inhibitor of phosphoinositide 3 kinase alpha harboring the H1047R mutation for the treatment of solid tumors, including breast cancer. The company is headquartered in Boulder, Colorado.
📈 OnKure Therapeutics, Inc. Historical Chart
📊 Statistics
-
Analyst 1 Year Price Target:
$32.00
-
Upside/Downside from Analyst Target:
1,222.31%
-
Broker Call:
12
-
Dividend Minimum 3 Year Yield:
0.00%
-
EPS Growth Range (1Y):
50-100%
-
Net Income Growth Range (1Y):
10-25%
-
Revenue Growth Range (1Y):
-
💰 Dividend History
| Year |
Annual Yield (%) |
Total Amount |
Current Yield (%) |
Ex Date |
Pay Date |
Particulars |
| 2024 |
- |
$0.100000 |
- |
2024-10-07 |
- |
Stock split |
|
Total Amount for 2024: $0.100000 |
📅 Earnings & EPS History for OnKure Therapeutics, Inc.
| Date | Reported EPS |
|---|
| 2026-05-04 (estimated upcoming) | - |
| 2026-03-09 (estimated upcoming) | - |
| 2025-11-05 (estimated upcoming) | - |
| 2025-11-04 (estimated upcoming) | - |
| 2025-08-11 (estimated upcoming) | - |
| 2025-08-10 (estimated upcoming) | - |
| 2025-05-06 | -1.19 |
| 2025-05-05 | - |
| 2025-05-04 | - |
| 2025-03-25 | - |
| 2025-03-10 | -1.37 |
| 2024-11-07 | -1.1 |
📰 Related News & Research
No related articles found for "onkure therapeutics".
